之江生物
(688317)
| 流通市值：44.64亿 | | | 总市值：44.64亿 |
| 流通股本：1.92亿 | | | 总股本：1.92亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 59,683,080.25 | 32,134,673.5 | 178,651,872.66 | 137,579,847.2 |
| 营业收入 | 59,683,080.25 | 32,134,673.5 | 178,651,872.66 | 137,579,847.2 |
| 二、营业总成本 | 81,319,431.82 | 51,227,131.69 | 160,107,466.65 | 130,299,732.01 |
| 营业成本 | 21,746,500.75 | 11,453,783.06 | 69,771,218.03 | 37,975,715.52 |
| 税金及附加 | 3,928,039.56 | 1,973,132.5 | 7,430,254.21 | 5,543,379.06 |
| 销售费用 | 19,827,377.12 | 12,034,590.16 | 55,586,644.23 | 49,172,418.13 |
| 管理费用 | 42,566,585.58 | 21,759,071.36 | 95,574,099.54 | 65,799,975.27 |
| 研发费用 | 29,330,590.87 | 13,572,425.59 | 58,783,335.09 | 39,074,589.3 |
| 财务费用 | -36,079,662.06 | -9,565,870.98 | -127,038,084.45 | -67,266,345.27 |
| 其中:利息费用 | 979,258.65 | 422,334.29 | 344,329.06 | 226,586.94 |
| 其中:利息收入 | 41,748,731.28 | 11,379,765.69 | 113,201,988.21 | 78,707,993.16 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 1,069,991.04 | 153,937.45 | 57,120.46 | - |
| 资产处置收益 | 25,777.74 | - | 39,305.59 | 39,305.59 |
| 资产减值损失(新) | 9,593,246.29 | 1,966,131.1 | -162,849,610.59 | -25,242,978.05 |
| 信用减值损失(新) | 167,355.39 | 647,735.7 | -10,871,402.11 | -215,377.15 |
| 其他收益 | 2,578,211.93 | 1,393,510.38 | 9,414,247.24 | 8,193,886.12 |
| 四、营业利润 | -8,201,769.18 | -14,931,143.56 | -145,665,933.4 | -9,945,048.3 |
| 加:营业外收入 | 1,637,142.23 | 428,526.74 | 2,067,210.93 | 67,466.24 |
| 减:营业外支出 | 1,035,621.33 | 917,167.33 | 6,972,188.25 | 1,066,383.99 |
| 五、利润总额 | -7,600,248.28 | -15,419,784.15 | -150,570,910.72 | -10,943,966.05 |
| 减:所得税费用 | 2,250,724.49 | 597,548.85 | -23,108,787.01 | 2,065,622.89 |
| 六、净利润 | -9,850,972.77 | -16,017,333 | -127,462,123.71 | -13,009,588.94 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -9,850,972.77 | -16,017,333 | -127,462,123.71 | -13,009,588.94 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -9,850,972.77 | -16,017,333 | -127,462,123.71 | -13,009,588.94 |
| 扣除非经常损益后的净利润 | -13,247,156.7 | -16,794,057.02 | -128,271,280.25 | -19,304,159.67 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.05 | -0.08 | -0.67 | -0.07 |
| (二)稀释每股收益 | -0.05 | -0.08 | -0.67 | -0.07 |
| 八、其他综合收益 | 541,904.08 | -13,955.73 | -4,374,088.21 | -3,191,985.54 |
| 归属于母公司股东的其他综合收益 | 541,904.08 | -13,955.73 | -4,374,088.21 | -3,191,985.54 |
| 九、综合收益总额 | -9,309,068.69 | -16,031,288.73 | -131,836,211.92 | -16,201,574.48 |
| 归属于母公司股东的综合收益总额 | -9,309,068.69 | -16,031,288.73 | -131,836,211.92 | -16,201,574.48 |
| 公告日期 | 2025-08-29 | 2025-04-30 | 2025-04-25 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |